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Figure 1: Log10 Calibration curve using Area Normalised Peak Height at 
422 cm-1, Log10 Calibration Range from 2x10
-10M to Lower Limit of 
Quantification.(LLOQ) = 3.5x10-13M. Insert linear calibration range 2.5X10-
12M to 2.5 x 10-13M, corresponding to blue dotted box. 
. 
Introduction 
Raman spectroscopy has recently achieved considerable interest for biomedical diagnosis and promising and 
innovative therapies.1 The emergence of compact laser sources, more sensitive detection equipment and 
portable instrumentation have all contributed to this interest. Here we report an ultrasensitive method for 
detecting bio-active compounds in biological samples by means of functionalized nanoparticles interrogated 
by surface enhanced Raman spectroscopy (SERS).  This method is applicable to the recovery and detection 
of many diagnostically important peptidyl analytes such as insulin, human growth hormone (somatotropin), 
mitogenic polypeptide growth factors (IGFs) and erythropoietin (EPO), as well as many small molecule 
analytes and metabolites. Our method was developed using the EPO system to demonstrate its utility in a 
complex yet well defined biological system. Recombinant human EPO (rHuEPO) and EPO analogues have 
successfully been used to treat anaemia in end-stage renal failure, chronic disorders and infections, cancer 
and AIDS.2 Current methods for EPO testing are lengthy, laborious and relatively insensitive to low 
concentrations.   
 
Methods 
Gold nanoparticles functionalised with anti-EPO antibody (3F6, 
MAIIA diagnostics) were used to: 
 
•Optimise the conditions for the interaction between the nanoparticle 
EPO. 
•Determine the major Raman peaks of the nanoparticle before and 
after reaction with EPO. 
•Develop a calibration curve for EPO. 
•Determine the ability of the nanoparticle to isolate EPO from urine,  
•Determine the ability of the Raman technique to distinguish 
between the EPO and rHuEPO. 
•Confirm that the nanoparticle do not cross react nonspecifically with 
other proteins in biological fluids.  
 
For the Raman studies, 10 µL each of the nanoparticle solution and 
analyte were mixed; pre-reacted and dried on a microscope slide 
covered with aluminum foil. When using biological fluids, the reacted 
nanoparticles were washed several times by centrifugation and 
resuspension before loading on the microscope slide. Samples were 
then examined using a Renishaw in Via Raman Microscope with 785 
nm laser. The Raman spectra were processed if necessary using 
Principal Component Analysis (PCA). 
 
 
 
 
 
 
 
Results 
The optimal time to react the nanoparticle with EPO was found to be 30 minutes. The limit of quantification was 
determined to be 3.5x10-13 M and a log10 calibration curve to 2×10
-10 M was obtained (R2 = 0.98). This 
contained a linear calibration region from 2.5x10-12 M to 2.5x10-13 M (R2 = 0.89). See figure 1.  
Urine varied from recombinant EPO spiked urine in region:1515 -1580 cm-1. See figure 2, and insert graph 
 
 
Discussion 
Our rapid screening methodology utilised commercially available anti-EPO antibodies to provide very high 
selectivity towards EPO protein in urine. These “smart sensors” interact with, trap and detect EPO.  SERS allows 
for ultra-trace detection (<<10-15 M) and quantification of EPO in biological fluids containing the normal 
concentration range of human endogenous EPO, e.g. urine and blood serum, 3  (Fig. 1), with minimal sample 
preparation. 
  
SERS detection differentiated between human endogenous EPO and rhEPO in un-purified urine (Fig 2). The 
elimination of sample preparation allows direct screening in biological fluids, significantly reducing the time 
required by current methods.  Antibody recognition against a variety of biological targets and the availability of 
portable commercial SERS analysers for rapid onsite testing provide broad diagnostic applicability in a robust 
analytical platform.  
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EPO: Lower Limit of Quantification 
Figure 3: Hierarchal PCA of Raman spectra (354 -1627 cm-1). Grey 
triangles are  unreacted nanoparticles,  black diamonds are 
nanoparticles  reacted with skim milk.   
SERS negative control for cross reactivity 
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Figure 2: PCA of Raman spectra (1515 -1580 cm-1). All urine samples are diluted 1:1. The larger data points are the average of six 
measurements. They are well separated even though they each contain measurements that are outliers to the model. Urine with: PBS pH 
7.4,   rHuEPO at 1x10-12M in PBS and  rHuEPO at 1x10-14M in PBS respectively. Insert: spectrum from Raman  with shaded box showing 
region used for chemometrics. 
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